🇺🇸 FDA
Patent

US 10561714

Factor IX polypeptides and methods of use thereof

granted A61KA61K38/38A61K38/4846

Quick answer

US patent 10561714 (Factor IX polypeptides and methods of use thereof) held by BIOVERATIV THERAPEUTICS INC. expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/38, A61K38/4846, A61K39/395, A61K39/39533